Oncology Position

[anonymous]

Desperation would be the only incentive for taking this job...

 

[anonymous]

Desperation would be the only incentive for taking this job...

Please elaborate. A lot of companies are very poorly ran and no pipeline. This job is at least attached to a stable company with a decent pipeline. Why do you feel it is so bad? The drug would be the only one with a CSCC indication.

 

[anonymous]

Please elaborate. A lot of companies are very poorly ran and no pipeline. This job is at least attached to a stable company with a decent pipeline. Why do you feel it is so bad? The drug would be the only one with a CSCC indication.

Ever launched an expensive drug with a miscellaneous j code in a very small, predominately medicare patient population? Easy peasy lemon squeezy! Better hope the pipeline delivers by year's end.

 

[anonymous]

Ever launched an expensive drug with a miscellaneous j code in a very small, predominately medicare patient population? Easy peasy lemon squeezy! Better hope the pipeline delivers by year's end.

And late entry to market. What #PD1 - 5th or 6th?

 

[anonymous]

Please elaborate. A lot of companies are very poorly ran and no pipeline. This job is at least attached to a stable company with a decent pipeline. Why do you feel it is so bad? The drug would be the only one with a CSCC indication.[/QUOTE

Ignore the haters. Great company, and lots of room for improvement in immune therapies. Go for it and good luck.

 

[anonymous]

And late entry to market. What #PD1 - 5th or 6th?

Unless you get an indication that is different than the other 4, you are dead n the water. Don't waste you time with this. These products will be like aspirin in 3 years. They all work the same.

 

[anonymous]

Unless you get an indication that is different than the other 4, you are dead n the water. Don't waste you time with this. These products will be like aspirin in 3 years. They all work the same.

True dat

 

[anonymous]

Unless you get an indication that is different than the other 4, you are dead n the water. Don't waste you time with this. These products will be like aspirin in 3 years. They all work the same.

Indeed, no reason to believe this one will be any better than others and that’s only the first hurdle. Remember this company has no prior experience in oncology, none.

 

[anonymous]

Indeed, no reason to believe this one will be any better than others and that’s only the first hurdle. Remember this company has no prior experience in oncology, none.

And didn't they put some dude from GSK Vaccines in charge of marketing this product? Nice outside-the-box thinking.....

 

[anonymous]

Unless you get an indication that is different than the other 4, you are dead n the water. Don't waste you time with this. These products will be like aspirin in 3 years. They all work the same.

https://www.sfgate.com/technology/b...-coming-late-to-a-group-of-drugs-12562445.php

nuff said!

 

[anonymous]

REGN leadership is smarter than everyone else. Hmmmm

 

[anonymous]

BLOCKBUSTER in the making.

 

[anonymous]

Filing soon

 

[anonymous]

No chance anyone with Oncology experience would go here. If you want to get into this space, very reasonable position. No chance to compete in I/O space. Just too late-too little

 

[anonymous]

No chance anyone with Oncology experience would go here. If you want to get into this space, very reasonable position. No chance to compete in I/O space. Just too late-too little

Tell that to the company that developed Eyelea, FDA approved 5 years after Lucentis.

The “better mousetrap” concept really does work.

 

[anonymous]

Tell that to the company that developed Eyelea, FDA approved 5 years after Lucentis.

The “better mousetrap” concept really does work.

 

[anonymous]

You certainly are not in Oncology. This is not a better mouse trap. But good luck with your interview.

 

[anonymous]

offers out and not impressive, offer not contingent on drug approval .....pass

 

[anonymous]

approval is a slam dunk

 

[anonymous]

Yes approval is likely, but commercial success is far from it. Look for 1/3 of the reps to have no sales 9 months into launch. Enjoy sitting in the back of the bus boys and girls, it's going to be a rough ride.